Betta Pharmaceuticals (300558.SZ): BPI-572270 Capsules Approved for Clinical Trials in Australia

Stock News
Sep 28

Betta Pharmaceuticals Co.,Ltd. (300558.SZ) has announced that its wholly-owned subsidiary, Hangzhou Jingyao Biotechnology Co., Ltd. ("Jingyao Biotech"), has received approval from Australia's Human Research Ethics Committee (HREC) for a Phase I/II clinical study of BPI-572270 capsules in patients with advanced solid tumors carrying specific RAS mutations.

The company has also completed clinical trial filing with Australia's Therapeutic Goods Administration (TGA).

This marks the company's first drug to be approved for clinical trials in Australia.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10